Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Raltitrexed-induced skin reaction].

D Topard1, I Hellier, M Ychou

  • 1Centre Régional de Lutte contre le Cancer, Val d'Aurelle, 34298 Montpellier Cedex 5.

Annales De Dermatologie Et De Venereologie
|February 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Tinea Capitis in children under 10 kg : Results from a French multicentre study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Value of tacrolimus 0.1% in the treatment of vitiligo in the era of targeted therapy.

Annales de dermatologie et de venereologie·2025
Same author

Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm.

Annales de dermatologie et de venereologie·2024
Same author

Isotretinoin: Past, present and future. A French perspective.

Annales de dermatologie et de venereologie·2024
Same author

Promoting clinical research in community-based practice: Threats and opportunities.

Annales de dermatologie et de venereologie·2024
Same author

Management of tinea capitis in children following the withdrawal of griseofulvin from the French market: A fast-track algorithm proposed by the Center of Evidence of the French Society of Dermatology.

Annales de dermatologie et de venereologie·2022

Raltitrexed, a thymine synthetase inhibitor for colorectal cancer, can cause pseudo-cellulitic skin reactions. These painful, generalized or localized skin reactions, though documented preclinically, are reported here for the first time in clinical practice.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Raltitrexed (Tomudex®) is a thymine synthetase inhibitor utilized in first-line treatment for metastatic colorectal cancer.
  • Preclinical studies indicated potential for skin reactions, but clinical documentation has been absent.
  • This report addresses the first documented clinical cases of skin reactions associated with raltitrexed therapy.

Observation:

  • Two patients, aged 75 and 65, received raltitrexed for rectal and sigmoid adenocarcinoma, respectively.
  • Both patients developed skin reactions 5-7 days post-treatment initiation, characterized by erythema, edema, and purpura.
  • Associated symptoms included asthenia, diarrhea, and moderate fever, with painful, pseudo-cellulitic lesions.

Findings:

  • Skin reactions varied from generalized to localized (legs) and were painful.

Related Experiment Videos

  • Lesions presented with pseudo-cellulitic features.
  • Reactions resolved within 15 days of drug discontinuation, followed by desquamation.

    • Implications:

    • This study highlights the occurrence of raltitrexed-induced pseudo-cellulitic skin reactions in clinical practice.
    • Clinicians should be aware of these potential dermatological adverse events.
    • Prompt recognition and drug withdrawal are crucial for managing these reactions.